Cargando…
Immunogenicity and functional characterization of Leishmania-derived hepatitis C virus envelope glycoprotein complex
Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are the main inducers of a cross-neutralizing antibody response which plays an important role in the early phase of viral infection. Correctly folded and immunologically active E1E2 complex can be expressed in mammalian cells, though the produ...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969751/ https://www.ncbi.nlm.nih.gov/pubmed/27481352 http://dx.doi.org/10.1038/srep30627 |
_version_ | 1782445836725125120 |
---|---|
author | Grzyb, Katarzyna Czarnota, Anna Brzozowska, Agnieszka Cieślik, Anna Rąbalski, Łukasz Tyborowska, Jolanta Bieńkowska-Szewczyk, Krystyna |
author_facet | Grzyb, Katarzyna Czarnota, Anna Brzozowska, Agnieszka Cieślik, Anna Rąbalski, Łukasz Tyborowska, Jolanta Bieńkowska-Szewczyk, Krystyna |
author_sort | Grzyb, Katarzyna |
collection | PubMed |
description | Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are the main inducers of a cross-neutralizing antibody response which plays an important role in the early phase of viral infection. Correctly folded and immunologically active E1E2 complex can be expressed in mammalian cells, though the production process might still prove restrictive, even if the immunological response of a vaccine candidate is positive. Here, we report a characterization and immunogenicity study of a full-length (fE1E2) and soluble version of the E1E2 complex (tE1E2) from genotype 1a, successfully expressed in the cells of Leishmania tarentolae. In a functional study, we confirmed the binding of both Leishmania-derived E1E2 complexes to the CD-81 receptor and the presence of the major epitopes participating in a neutralizing antibody response. Both complexes were proved to be highly immunogenic in mice and elicited neutralizing antibody response. Moreover, cross-reactivity of the mouse sera was detected for all tested HCV genotypes with the highest signal intensity observed for genotypes 1a, 1b, 5 and 6. Since the development of a prophylactic vaccine against HCV is still needed to control the global infection, our Leishmania-derived E1E2 glycoproteins could be considered a potential cost-effective vaccine candidate. |
format | Online Article Text |
id | pubmed-4969751 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-49697512016-08-11 Immunogenicity and functional characterization of Leishmania-derived hepatitis C virus envelope glycoprotein complex Grzyb, Katarzyna Czarnota, Anna Brzozowska, Agnieszka Cieślik, Anna Rąbalski, Łukasz Tyborowska, Jolanta Bieńkowska-Szewczyk, Krystyna Sci Rep Article Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are the main inducers of a cross-neutralizing antibody response which plays an important role in the early phase of viral infection. Correctly folded and immunologically active E1E2 complex can be expressed in mammalian cells, though the production process might still prove restrictive, even if the immunological response of a vaccine candidate is positive. Here, we report a characterization and immunogenicity study of a full-length (fE1E2) and soluble version of the E1E2 complex (tE1E2) from genotype 1a, successfully expressed in the cells of Leishmania tarentolae. In a functional study, we confirmed the binding of both Leishmania-derived E1E2 complexes to the CD-81 receptor and the presence of the major epitopes participating in a neutralizing antibody response. Both complexes were proved to be highly immunogenic in mice and elicited neutralizing antibody response. Moreover, cross-reactivity of the mouse sera was detected for all tested HCV genotypes with the highest signal intensity observed for genotypes 1a, 1b, 5 and 6. Since the development of a prophylactic vaccine against HCV is still needed to control the global infection, our Leishmania-derived E1E2 glycoproteins could be considered a potential cost-effective vaccine candidate. Nature Publishing Group 2016-08-02 /pmc/articles/PMC4969751/ /pubmed/27481352 http://dx.doi.org/10.1038/srep30627 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Grzyb, Katarzyna Czarnota, Anna Brzozowska, Agnieszka Cieślik, Anna Rąbalski, Łukasz Tyborowska, Jolanta Bieńkowska-Szewczyk, Krystyna Immunogenicity and functional characterization of Leishmania-derived hepatitis C virus envelope glycoprotein complex |
title | Immunogenicity and functional characterization of Leishmania-derived hepatitis C virus envelope glycoprotein complex |
title_full | Immunogenicity and functional characterization of Leishmania-derived hepatitis C virus envelope glycoprotein complex |
title_fullStr | Immunogenicity and functional characterization of Leishmania-derived hepatitis C virus envelope glycoprotein complex |
title_full_unstemmed | Immunogenicity and functional characterization of Leishmania-derived hepatitis C virus envelope glycoprotein complex |
title_short | Immunogenicity and functional characterization of Leishmania-derived hepatitis C virus envelope glycoprotein complex |
title_sort | immunogenicity and functional characterization of leishmania-derived hepatitis c virus envelope glycoprotein complex |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969751/ https://www.ncbi.nlm.nih.gov/pubmed/27481352 http://dx.doi.org/10.1038/srep30627 |
work_keys_str_mv | AT grzybkatarzyna immunogenicityandfunctionalcharacterizationofleishmaniaderivedhepatitiscvirusenvelopeglycoproteincomplex AT czarnotaanna immunogenicityandfunctionalcharacterizationofleishmaniaderivedhepatitiscvirusenvelopeglycoproteincomplex AT brzozowskaagnieszka immunogenicityandfunctionalcharacterizationofleishmaniaderivedhepatitiscvirusenvelopeglycoproteincomplex AT cieslikanna immunogenicityandfunctionalcharacterizationofleishmaniaderivedhepatitiscvirusenvelopeglycoproteincomplex AT rabalskiłukasz immunogenicityandfunctionalcharacterizationofleishmaniaderivedhepatitiscvirusenvelopeglycoproteincomplex AT tyborowskajolanta immunogenicityandfunctionalcharacterizationofleishmaniaderivedhepatitiscvirusenvelopeglycoproteincomplex AT bienkowskaszewczykkrystyna immunogenicityandfunctionalcharacterizationofleishmaniaderivedhepatitiscvirusenvelopeglycoproteincomplex |